Search
Illumina’s CEO Jacob Thaysen shares highlights from the company’s ‘Strategy Update' today and his vision for the business going forward
Jacob Thaysen covers Illumina’s business today, including the NovaSeq X platform, multiomics, clinical and pharma industry applications,...
Aug 13, 2024
Avidity Biosciences' CEO Sarah Boyce discusses the company's Exon 44 skipping data in DMD that showed a 25% increase in dystrophin production
She describes how this PMO based antibody oligonucleotide conjugate works and why she believes the result validates her belief that...
Aug 13, 2024
Scholar Rock's CEO on a big phase 3 readout coming later this year in SMA, myostatin inhibition for obesity, and more
Jay Backstrom describes the company's approach of targeting the latent form of growth factors, the importance of the upcoming SAPPHIRE...
Aug 9, 2024
Nello Mainolfi shares an update on Kymera and the progress of the protein degradation field
He gives updates on programs such as IRAK4, STAT6, TYK2, and STAT3, and describes learnings in protein degradation that Kymera has...
Aug 9, 2024
Servier's U.S. CEO discusses FDA approval of Voranigo, a targeted therapy for a common type of brain cancer
David Lee describes the glioma brain cancer population this IHD1/2 targeting therapy is for, Servier's experience commercializing cancer...
Aug 7, 2024
The CEO of UK based Levicept shares background on the company's neurotrophin-3 inhibiting fusion protein, which they say succeeded today in pain management in an osteoarthritis phase 2 study
Eliot Forster describes the scientific rational of inhibiting NT-3 while avoiding nerve growth factor and the side effects that come with...
Aug 6, 2024
Stoke Therapeutics' CEO Ed Kaye on using RNA medicines to upregulate protein expression, and the company's progress in Dravet Syndrome
He describes the unique science that Stoke was founded on, how phase 1/2a data in Dravet appears to show they are reversing this genetic...
Aug 5, 2024
Adaptimmune's CEO discusses last night's FDA accelerated approval of TECELRA, a TCR-based engineered cell therapy for synovial sarcoma
Adrian Rawcliffe describes how the treatment works, the expected rollout and cost, and what this means for TCR therapies going forward.
Aug 2, 2024
Cambridge, UK based Healx, an AI powered rare disease company, announced a $47M series C financing today
Co-founder and CEO Tim Guilliams describes the investors who led the round and how it will allow Healx to advance its lead program for...
Aug 1, 2024
io9 published data in the Journal of Clinical Oncology today demonstrating that its AI biomarker platform OncoGaze identified HRD-positive patients from routine tissue slides
CEO Greg Hamilton describes how patients who were diagnosed with this software platform had better outcomes, how it might increase the...
Jul 31, 2024
Autobahn Therapeutics announced a $100M series C this week as it prepares to move its thyromimetic into phase 2 for MDD and bipolar disorder depression
CEO Kevin Finney describes the rationale for using a TRβ agonist and how this program leverages Autobahn's brain-targeting chemistry...
Jul 26, 2024
AI x Bio Summit: The Co-Founder of Kernal Bio describes designing mRNA therapies that are selectively delivered to, and translated by, specific cells in the body
Yusuf Erkul explains the four components that go into getting mRNA to the right location in the body and to be translated in the right...
Jul 25, 2024
AI x Bio Summit: Generate Biomedicines' CEO Mike Nally gives an update on the company's clinical and emerging programs
He describes clinical programs targeting COVID and TSLP, as well as emerging programs in the ADC space, TL1A, IL13, and more.
Jul 25, 2024
AI x Bio Summit: Co-Founder Transon Nguyen describes how AI is enabling Eigen Therapeutics to become a discovery engine for priming therapies
He explains how the goal of Eigen is to help up-regulate antigens of interest and how technologies today allow a smaller startup to...
Jul 25, 2024
Philadelphia area based XyloCor is developing a gene therapy with the goal of helping to revascularize the heart for refractory angina patients
CEO Al Gianchetti explains that the company recently released final results from a phase 1/2 clinical trial and how XyloCor is set to...
Jul 24, 2024
GRO Biosciences announced a $60 million series B today to help advance its pipeline that is rooted in adding non-standard amino acid (NSAA) chemistries to therapies.
Co-founder and CEO Dan Mandell discusses the company’s approach, and describes how this will allow GRObio to advance its lead program for...
Jul 19, 2024
The founder of Click Therapeutics on the digital therapeutics space and the regulatory opportunity for combining medicines with apps
David Klein describes how the digital therapeutics space works and highlights Click's programs and partnerships with large pharmaceutical...
Jul 18, 2024
Stevenage, UK based Antikor Biopharma is developing ADCs using 'OptiLinked' smaller antibody fragments
CEO Mahendra Deonarian describes the potential advantages of this approach over traditional ADCs and talks about the company's lead...
Jul 17, 2024
Stevenage, UK based Autifony Therapeutics has been building a CNS pipeline from its expertise in ion channel drug discovery
Founder & CEO Charles Large describes the scientific foundation Autifony has built in ion channel science and how the company is...
Jul 17, 2024
Stevenage, UK based Spur Therapeutics is readying to take its gene therapy for Gaucher disease into phase 3
CEO Michael Parini describes how clinical results Spur has seen to date in six patients, with more data to come later this year, has...
Jul 17, 2024
.png){kind=logo}
